-
Mashup Score: 0
The phase 3 KeyVibe-003, KeyVibe-007, and KEYFORM-008 trials investigating vibostolimab and favezelimab have been discontinued.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
The phase 3 KeyVibe-003, KeyVibe-007, and KEYFORM-008 trials investigating vibostolimab and favezelimab have been discontinued.
Clinical development programs including the KeyVibe program investigating the anti–TIGIT antibody vibostolimab and the KEYFORM program investigating the anti–LAG-3 agent favezelimab have been discontinued. #NSCLC #lymsm https://t.co/DQakHmBNST https://t.co/MAYVE2cOZw